Journey Medical Corp
Fortress Biotech FBIO | 0.00 | |
Journey Medical DERM | 0.00 |
Journey Medical Corp DERM.OQ DERM.O is expected to show a rise in quarterly revenue when it reports results on May 13 for the period ending March 31 2026
The Scottsdale Arizona-based company is expected to report a 21.4% increase in revenue to $15.948 million from $13.14 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Journey Medical Corp is for a loss of 8 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Journey Medical Corp is $13.00, about 156.4% above its last closing price of $5.07
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING |
STARMINESMARTESTIMATE® |
LSEG IBES ESTIMATE |
ACTUAL |
BEAT, MET, MISSED |
SURPRISE % |
Dec. 31 2025 |
-0.07 |
-0.06 |
-0.05 |
Beat |
20 |
Sep. 30 2025 |
-0.04 |
-0.05 |
-0.09 |
Missed |
-89.5 |
Jun. 30 2025 |
-0.10 |
-0.10 |
-0.16 |
Missed |
-52.4 |
Mar. 31 2025 |
-0.23 |
-0.24 |
-0.18 |
Beat |
24.2 |
Dec. 31 2024 |
-0.35 |
-0.15 |
Beat |
57.4 |
|
Sep. 30 2024 |
-0.14 |
-0.15 |
-0.17 |
Missed |
-15.3 |
Jun. 30 2024 |
-0.14 |
-0.14 |
-0.17 |
Missed |
-18.6 |
Mar. 31 2024 |
-0.23 |
-0.23 |
-0.53 |
Missed |
-125.5 |
This summary was machine generated May 11 at 21:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)